Philip Leming
Overview
Explore the profile of Philip Leming including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
1219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al.
J Clin Oncol
. 2018 Mar;
36(17):1675-1684.
PMID: 29570421
Purpose In two phase III studies, nivolumab, a programmed death-1 (PD-1) inhibitor antibody, improved overall survival (OS) versus docetaxel in pretreated advanced non-small-cell lung cancer (NSCLC). We report 5-year follow-up...
2.
Gettinger S, Horn L, Gandhi L, Spigel D, Antonia S, Rizvi N, et al.
J Clin Oncol
. 2015 Apr;
33(18):2004-12.
PMID: 25897158
Purpose: Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well...
3.
Hodi F, Lee S, Mcdermott D, Rao U, Butterfield L, Tarhini A, et al.
JAMA
. 2014 Nov;
312(17):1744-53.
PMID: 25369488
Importance: Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade with ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine combinations demonstrate therapeutic synergy in...
4.
Flaherty K, Lee S, Zhao F, Schuchter L, Flaherty L, Kefford R, et al.
J Clin Oncol
. 2012 Dec;
31(3):373-9.
PMID: 23248256
Purpose: The primary objective of this study was to determine whether carboplatin, paclitaxel, and sorafenib (CPS) improve overall survival (OS) compared with carboplatin and paclitaxel (CP) in chemotherapy-naive patients with...